Abstract:Emerging variants of SARS-CoV-2 and drug-resistant mutants jeopardizes the efficacies of currently deployed therapies, highlighting the necessity for development of more efficacious antivirals. Given the highly conserved sequence and pivotal role of the papain-like protease (PLpro) in the viral replication and pathogenesis, it is a promising yet a challenging drug target. Additionally, PLpro plays a very important role in modulation of host immune response by deubiquitinating (DUBs) or deISGylating host proteins. Thus, targeting PLpro serves as a two-pronged approach to abate SARS-CoV-2. Owing to the structural and functional similarities of PLpro with the cellular DUB enzymes, this study developed an in-house library of DUB inhibitors and leveraged structure-based identification tools to identify five promising inhibitors targeting the Ubiquitin/ISG15 binding site and the known BL2 groove pocket of PLpro. The proteolytic activity of purified PLpro was markedly inhibited by four of these compounds and these displayed potent antiviral efficacies against SARS-CoV2 infection in a dose dependent manner. Crystal structure of SARS-CoV-2 PLpro in complex with two of these DUB inhibitors, the Linagliptin and Lithocholic acid revealed insights into the molecular inhibition mechanism with unique interactions within the Ubiquitin/ISG15 binding site (S2 site; Phe69, His73, Asn128, His175) and the substrate binding cleft. Additionally, oral and intraperitoneal treatments with Linagliptin increased survival, reduced lung viral load, and ameliorated histopathological damage in mouse-adapted model of SARS-CoV-2 infection. For the first time, this study demonstrated a two-pronged strategy using DUB inhibitors that target the PLpro and simultaneously reinstates the host's immune response against SARS-CoV-2.

Disrupting protease and deubiquitinase activities of SARS-CoV-2 papain-like protease by natural and synthetic products discovered through multiple computational and biochemical approaches

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Discovery of Novel Natural Inhibitors Against SARS-CoV-2 Main Protease: A Rational Approach to Antiviral Therapeutics

Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease

In Silico Screening of Semi-Synthesized Compounds as Potential Inhibitors for SARS-CoV-2 Papain-like Protease: Pharmacophoric Features, Molecular Docking, ADMET, Toxicity and DFT Studies

Crystal structure and activity profiling of deubiquitinating inhibitors-bound to SARS-CoV-2 papain like protease revealed new allosteric sites for antiviral therapies

Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2

Discovery of Novel and Highly Potent Inhibitors of SARS CoV-2 Papain-Like Protease Through Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, Molecular Dynamics Simulations, and Biological Evaluation

Activity profiling of deubiquitinating inhibitors-bound to SARS-CoV-2 papain like protease with antiviral efficacy in murine infection model

Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2

Drug Repurposing for the SARS‐CoV‐2 Papain‐Like Protease

Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity

Integrated computational and experimental approaches to identify new papain-like protease inhibitors

Identification of Novel Allosteric Sites of SARS-CoV-2 Papain-Like Protease (PLpro) for the Development of COVID-19 Antivirals

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2

In-silico approaches for identification of compounds inhibiting SARS-CoV-2 3CL protease

Naphthalen-1-ylethanamine-containing small molecule inhibitors of the papain-like protease of SARS-CoV-2

Repurposing the antibacterial drugs for inhibition of SARS-CoV2-PLpro using molecular docking, MD simulation and binding energy calculation

Modeling of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-2 considering the protein flexibility by using molecular dynamics and cross-docking

Crystal structure of SARS-CoV-2 papain-like protease

Integrated Exploration of Pyranocoumarin Derivatives as Synergistic Inhibitors of Dual-target for Mpro and PLpro Proteins of SARS-CoV-2 through Molecular Docking, ADMET Analysis, and Molecular Dynamics Simulation